Speakers

Eberhard Kwiatkowski

Eberhard Kwiatkowski

PharmAdvantageIT

Stefan Münch

Stefan Münch

Körber Pharma Consulting

Yves Samson

Yves Samson

Kereon

Does CSA lead to changes during the validation of computerised systems? - Opportunities and limitations in the pharmaceutical industry.


Target Group

Staff from the Life Sciences Business (pharmaceuticals / medical devices / suppliers / consultancy) in the following areas:
  • IT
  • Quality Assurance
  • Manufacturing
  • Quality Control

Objectives

Why should you attend this event?

  • The background to the FDA’s CSA (Computer Software Assurance) initiative will be presented
  • Does CSA replace CSV? You will learn about the connections and differences between CSV (Computerised System Validation) and CSA
  • What benefits does CSA offer for software validation?

CSA is the result of an initiative by the life sciences industry and the FDA to promote a risk-based approach that focuses more strongly on software quality while significantly reducing the documentation burden. Following an initial draft in 2022, the FDA published the final version on 3 February 2026.

 


Programme

Background / Application to Medical Devices / Applicable to Pharmaceuticals?
  • Medical devices vs pharmaceutical GxP
    • European Union
    • USA
  • 2017–2026: CSA development. From the triggers to the final version (February 2026)
  • Differences in context between medical devices and pharmaceutical applications and devices
CSA Risk Framework

Identifying the Intended Use

  • When is validation necessary?
  • Risk-based scaling
  • Procedure for using the cloud

Determining the Risk-Based Approach

  • Risk-based approach according to ISO 13485
  • Comparison with ISO 14971
  • Identification of risks in software applications
  • Binary or spectrum – which is it?
Production of Quality System Software Changes
  • How much validation evidence is needed?
  • Defined user requirements
  • Validation of off-the-shelf software and automated equipment
  • Validated according to a written procedure for the particular intended use

Determining the Appropriate Activities

  • From specifications to testing
  • 50 shades of testing

Additional Considerations for Assurance Activities

  • Activities and established processes that provide control in production
  • Additional process controls, including activities to reduce cybersecurity exposure
  • The data and information collected periodically or continuously by the software
  • The use of tools supporting software development and system life cycle activities
  • The use of testing and results carried out in iterative cycles

Establishing the Appropriate Records

  • How much quality assurance documentation is required?
  • Effective use of digital resources

Considerations for Electronic Records Requirements

  • When does 21 CFR Part 11 apply?
  • Which records are affected under 21 CFR Part 820?
  • How do I explain this to the regulatory authority?

Examples:

Example 1: Nonconformance Management System
  • Standard (off-the-shelf) systems and the effective use of supplier involvement
  • What is expected / what should be done?
Example 2: Learning Management System (LMS)
  • Learning Management System (LMS) applying a risk-based approach
  • Established SOP for evaluating suppliers
  • Developing a risk-based assurance strategy

CSV vs. CSA – Relationship to other Regulations

  • Clarification of terms
  • CSV vs. CSA – Key differences
  • Relationship to other regulations (ISO standard environment)

Assessment – What is Good, Useful, Unsuitable

  • Critical thinking: The CSA’s ‘poltergeist’
  • Optimising compliance activities
    • Focus on what is truly relevant and necessary
  • A computer-based system is not the same as computer software
  • What about quality control equipment and production facilities?


Further Information

Technical Requirements
We use Webex for our live online training courses and webinars. At www.gmp-compliance.org/training/online-training-technical-information you will find all the information you Need to participate in our events and you can check if your System meets the necessary requirements to participate. If the Installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.
 
Fees (per delegate, plus VAT)
 
ECA Members EUR 1,090
APIC Members EUR 1,190
Non-ECA Members EUR 1,290
EU GMP Inspectorates EUR 645
The conference fee is payable in advance after receipt of invoice.

Presentations/Certificate
The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language
The official conference language will be English.
 
Contacts
Questions regarding content:
Dr Andreas Mangel, +49 6221 84 44-41, mangel@concept-heidelberg.de
Questions regarding Organisation:
Mr Rouwen Schopka, +49 6221 84 44-13, schopka@concept-heidelberg.de


Date & Time

Wed, 10 Feb 2027, 09:00 -17:00 h
All times mentioned are CET.

Costs

ECA-Member*: € 1090,-
Regular Fee*: € 1290,-
EU/GMP Inspectorates*: € 645,-
APIC Member Discount*: € 1190,-

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

icon
Recording/ Additional dates on-site
not available
Recording/ Additional dates on-site
not available
stop

This course is part of the GMP Certification Programme "ECA Certified Computer Validation Manager"

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Woman with headset

Go back

What participants say about our courses and conferences

"Great material and speakers" and "Great speakers a lot of experience and sharing"

Felipe Gonzalez, Mucos Emulsionsgesellschaft mbH
Live Online Training - Granulation & Tableting, September 2024

“I found the course eye opening and very well organized.”

Jozsef Maklary, Veolia Industries Austria GmbH
The GMP-Compliance Manager, October 2025

"I am so grateful for having attended this course. Great job from all, and very profitable. Thanks!”

Alba Aranda Cuesta, Kern Pharma
KPIs and Quality Metrics, Berlin, Germany, April 2025

"The lectures were very informative, interesting and entertaining."

Albert Godoy Hernández, Company synaffix
Live Online Training - GMP Auditor Practice, October 2024

"Really useful training which I will use in my daily work."

Regina Mommaerts, Galapagos NV
Live Online Training - GMP Auditor Practice, October 2024

"Wonderful format of the sessions: Good range of participations and experience in the team. Would love to attend another one soon."

Roopasi Mathi, Wacker Biotech B.V.
Live Online Training - GMP Auditor Practice, October 2024

"Very good balance between general and detailed information"

Dr Ralf Albrecht, Tillotts Pharma AG
Live Online Training - Granulation & Tableting
September 2024

"Nice presentations: easy understanding, quite visual"

Susana Manrique, Boehringer Ingelheim España, S.A,
Live Online Training - Granulation & Tableting, September 2024

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

 

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

 

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

 

 

“Both, organizers and lecturers were very friendly, open for discussions and extremely constructive. The course was a valuable experience for me.”

Maria Dimitrova, NKN Law Firm
Pharmaceutical Contracts: GMP and Legal Compliance, March 2025